Results
|
101.
|
|
|
102.
|
Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways. [electronic resource] by
- He, Wan
- Xu, Zhijian
- Song, Dongliang
- Zhang, Hui
- Li, Bo
- Gao, Lu
- Zhang, Yong
- Feng, Qilin
- Yu, Dandan
- Hu, Liangning
- Chen, Gege
- Tao, Yi
- Wu, Xiaosong
- Shi, Jumei
- Zhu, Weiliang
Producer: 20200226
In:
Life sciences vol. 243
Availability: No items available.
|
|
103.
|
|
|
104.
|
Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway. [electronic resource] by
- Xiao, Wenqin
- Xu, Zhijian
- Chang, Shuaikang
- Li, Bo
- Yu, Dandan
- Wu, Huiqun
- Xie, Yongsheng
- Wang, Yingcong
- Xie, Bingqian
- Sun, Xi
- Kong, Yuanyuan
- Lan, Xiucai
- Bu, Wenxuan
- Chen, Gege
- Gao, Lu
- Wu, Xiaosong
- Shi, Jumei
- Zhu, Weiliang
Producer: 20191129
In:
Cancer letters vol. 444
Availability: No items available.
|
|
105.
|
Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. [electronic resource] by
- Shi, Xinan
- Li, Hongjian
- Shi, Anhua
- Yao, Hong
- Ke, Kunbin
- Dong, Chao
- Zhu, Ying
- Qin, Yi
- Ding, Ying
- He, Yan Hong
- Liu, Xu
- Li, Ling
- Lei, Ling
- Hai, Qingshan
- Chen, Wei
- Leung, Kwong-Sak
- Wong, Man-Hon
- Kung, Hsiang-Fu
- Lin, Marie Chia-Mi
Producer: 20181102
In:
Oncology reports vol. 40
Availability: No items available.
|